Close Menu

NEW YORK (GenomeWeb) — Fulgent Genetics reported after the close of the market on Tuesday a 15 percent increase in its first quarter revenues.

For the three-month period ended March 31, Fulgent posted revenues of $5.4 million versus $4.7 million in the same quarter last year. The firm said it delivered 7,530 billable genetic tests during Q1, a 63 percent year-over-year increase.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.